Danish researchers turned to Reddit to study side effects of weight loss drugs like Wegovy and Ozempic, mining thousands of patient posts to track real world experiences beyond clinical trials. The approach highlights both the power of crowdsourced health data and the growing recognition that official studies may miss what patients actually endure when they take these medications long term.
A team from the University of Copenhagen analyzed Reddit discussions to identify side effects from GLP-1 drugs, the class that includes semaglutide, marketed as Wegovy for weight loss and Ozempic for diabetes. As reported by TV2, the researchers sifted through patient posts where users detailed experiences that often go unreported in formal medical channels. The study taps into a frustration many of us living here know well. Denmark’s healthcare system is thorough, but it often relies on patients to raise concerns during brief consultations, and not everyone does.
Reddit offers something clinical trials cannot: unfiltered honesty. People post when they feel awful at 2 a.m., when nausea hits hard, or when their hair starts falling out in clumps. They compare notes, share coping strategies, and sometimes decide to quit the drug altogether. That kind of granular, messy data does not fit neatly into a phase 3 trial report, but it matters enormously to anyone considering these medications.
What Patients Actually Report
The usual suspects show up in both Reddit threads and official side effect profiles. Gastrointestinal issues dominate: nausea, vomiting, diarrhea, constipation, abdominal pain. Most clinical sources note these affect a majority of users early on, tapering as the body adjusts or the dose escalates slowly. Around 4% of patients discontinue during dose escalation because they cannot tolerate it. Fatigue, headache, dizziness, and a racing heart also appear frequently.
But Reddit discussions often spotlight effects that clinical summaries downplay. Hair loss, for instance, affects about 2.5% of Wegovy users according to Danish clinic data, compared to 1% on placebo. That may sound minor statistically, but for the person watching clumps come out in the shower, it is devastating. Heart rate increases average around 3 beats per minute, yet 67% of patients experience a jump of more than 10 bpm, which can feel unsettling even if doctors deem it safe.
I have watched this play out among friends here in Copenhagen. One colleague lost significant weight on Wegovy but quit after six months because the nausea never really stopped. She felt she had traded one health problem for another. That kind of calculation rarely makes it into trial data, but it is all over Reddit.
The Long Game and the Rebound Problem
Wegovy delivers around 16% weight loss after 68 weeks in clinical settings, but the weight comes back when people stop taking it. A recent meta-analysis questioned the cost effectiveness of these drugs precisely because patients regain their original weight roughly 1.5 years after stopping. No one has 20 or 30 year data on what happens if you stay on semaglutide for life. We are in uncharted territory.
This uncertainty weighs heavily in Denmark, where public health budgets matter and the system generally favors interventions with durable outcomes. If these drugs require lifelong use to maintain weight loss, that is a very different proposition than a treatment you take for a few years and move on. The price debates and insurance coverage questions get more complicated when permanence is not on the table.
Reddit users often discuss this frankly. They weigh whether the side effects are worth it if they have to inject weekly forever. Some decide yes, others bail. The study captures that ambivalence in a way official channels do not.
Novo Nordisk Faces New Pressure
This research arrives as Novo Nordisk, Denmark’s pharmaceutical giant, faces intensifying competition. The company’s CagriSema, a next generation combination drug, recently posted 23% weight loss in trials, falling short of Eli Lilly’s tirzepatide at 25.5%. That marks the second head to head loss to Lilly’s drug in recent months. Novo remains optimistic, pointing to higher dose studies starting mid 2026 and potential FDA approval later this year, but the stumble stings.
Meanwhile, Novo launched an oral Wegovy pill in the United States in early 2026, aiming to ease adherence issues tied to weekly injections. That innovation might address some of the injection related complaints flooding Reddit, though gastrointestinal side effects likely persist regardless of delivery method. The company also reported promising phase 2 data for UBT251 in China, showing nearly 10% weight loss in diabetes patients, signaling a push beyond semaglutide.
But scrutiny is mounting. As weight loss outcomes generate new medical needs and costs, regulators and patients alike are asking harder questions about what these drugs demand in return for their results.
Why Reddit Matters for Expats
For those of us living in Denmark as expats, navigating healthcare already involves translation, both literal and cultural. The system here assumes you will advocate for yourself, but it does not always make space for the kind of extended conversation these side effects warrant. Reddit fills that gap. It is where English speaking patients share experiences, compare Danish doctors’ responses, and figure out whether what they are feeling is normal or alarming.
The University of Copenhagen study legitimizes what many of us already intuited: patient forums hold real value. They reveal patterns that take years to show up in formal pharmacovigilance. They also expose the lived reality behind the statistics, the 4% who quit, the 2.5% losing hair, the 67% with racing hearts. Those percentages represent real people making hard choices about their bodies and their futures.
Denmark prides itself on evidence based medicine, and rightly so. But evidence comes in many forms. Sometimes it is a phase 3 trial. Sometimes it is a Reddit thread at midnight where someone finally admits they cannot take it anymore. Both matter. Both deserve attention. This study suggests Danish researchers are starting to agree.
Sources and References
The Danish Dream: Will Ozempic Prices Increase Novo Nordisks Tariff Concerns
The Danish Dream: Wegovy Weight Loss Spurs Skin Removal Surgeries
The Danish Dream: Health Insurance in Denmark
